Close Menu

NEW YORK – Vermillion reported after the close of the market on Tuesday a 66 percent year-over-year jump in its third quarter revenues.

For the three months ended Sept. 30, the Austin, Texas-based cancer diagnostics firm said that total revenues rose to $1.3 million from $774,000 in the year-ago quarter.

Product revenues were $1.2 million, up 68 percent from $738,870 in Q3 2018. Service revenues from the company's Aspira IVD business were up 26 percent to $44,000 from $35,000 in Q3 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.